Allogene Therapeutics, Inc. Common Stock (ALLO) is a publicly traded Healthcare sector company. As of August 18, 2026, ALLO trades at $2.08 with a market cap of $708.26M and a P/E ratio of -2.35. ALLO moved +0.98% today. Year to date, ALLO is +49.63%; over the trailing twelve months it is +91.59%. Its 52-week range spans $0.86 to $4.46. Analyst consensus is strong buy with an average price target of $10.25. Rallies surfaces ALLO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
6 analysts cover ALLO: 0 strong buy, 6 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $10.25.
| Metric | Value |
|---|---|
| Price | $2.08 |
| Market Cap | $708.26M |
| P/E Ratio | -2.35 |
| EPS | $-0.87 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.46 |
| 52-Week Low | $0.86 |
| Volume | 2.14M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-190.89M |
| Gross Margin | 0.00% |
6 analysts cover ALLO: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.25.